AAI101/cefepime

Drug Profile

AAI101/cefepime

Alternative Names: AAI 101/cefepime; AAI-202; FEP/AAI101

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allecra Therapeutics
  • Class Antibacterials; Beta-lactams
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Urinary tract infections

Most Recent Events

  • 04 Dec 2017 Allecra Therapeutics plans a phase III trial
  • 04 Oct 2017 Interim preclinical studies in Urinary tract infections presented at the IDWeek 2017
  • 06 Sep 2017 AAI101/cefepime receives Qualified Infectious Disease Product status for Intra-abdominal infections in USA prior to September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top